Center for Kidney Disease, Second Affiliated Hospital, Nanjing Medical University, Nanjing, China.
State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University Advanced Institute of Life Sciences, Nanjing, China.
Cell Death Dis. 2020 Jan 13;11(1):26. doi: 10.1038/s41419-019-2219-4.
Mitochondrial dysfunction leads to loss of renal function and structure; however, the precise mechanisms by which mitochondrial function can regulate renal fibrosis remain unclear. Proximal tubular cells (PTCs) prefer fatty acid oxidation as their energy source and dysregulation of lipid metabolism has been linked to tubulointerstitial fibrosis (TIF). Here, we demonstrated that mitochondrial uncoupling protein 2 (UCP2) regulates TIF through the stimulation of lipid deposition and extracellular matrix (ECM) accumulation. We show that UCP2 expression was increased in human biopsy sample and mouse kidney tissues with TIF. Moreover, UCP2-deficient mice displayed mitigated renal fibrosis in I/R-induced mouse model of TIF. Consistent with these results, UCP2 deficiency displayed reduced lipid deposition and ECM accumulation in vivo and in vitro. In UCP2-deficient PTCs, inhibition of TIF resulted from downregulation of hypoxia-inducible factor-1α (HIF-1α), a key regulator of lipid metabolism and ECM accumulation. Furthermore, we describe a molecular mechanism by which UCP2 regulates HIF-1α stabilization through regulation of mitochondrial respiration and tissue hypoxia during TIF. HIF-1α inhibition by siRNA suppressed lipid and ECM accumulation by restoration of PPARα and CPT1α, as well as suppression of fibronectin and collagen I expression in PTCs. In conclusion, our results suggest that UCP2 regulates TIF by inducing the HIF-1α stabilization pathway in tubular cells. These results identify UCP2 as a potential therapeutic target in treating chronic renal fibrosis.
线粒体功能障碍导致肾功能和结构丧失;然而,线粒体功能如何调节肾纤维化的确切机制尚不清楚。近端肾小管细胞(PTC)优先利用脂肪酸氧化作为其能量来源,脂质代谢失调与肾小管间质纤维化(TIF)有关。在这里,我们证明了线粒体解偶联蛋白 2(UCP2)通过刺激脂质沉积和细胞外基质(ECM)积累来调节 TIF。我们表明,UCP2 在有 TIF 的人类活检样本和小鼠肾脏组织中的表达增加。此外,UCP2 缺陷小鼠在 I/R 诱导的 TIF 小鼠模型中表现出减轻的肾纤维化。与这些结果一致,UCP2 缺陷在体内和体外显示出减少的脂质沉积和 ECM 积累。在 UCP2 缺陷的 PTC 中,TIF 的抑制是由于缺氧诱导因子-1α(HIF-1α)的下调,HIF-1α 是脂质代谢和 ECM 积累的关键调节剂。此外,我们描述了 UCP2 通过调节 TIF 期间的线粒体呼吸和组织缺氧来调节 HIF-1α 稳定的分子机制。用 siRNA 抑制 HIF-1α 通过恢复 PPARα 和 CPT1α 以及抑制 PTC 中纤连蛋白和胶原 I 的表达来抑制脂质和 ECM 积累。总之,我们的结果表明,UCP2 通过诱导管状细胞中的 HIF-1α 稳定途径来调节 TIF。这些结果表明 UCP2 是治疗慢性肾纤维化的潜在治疗靶点。